XAIR - Medical Device Player Beyond Air's Subsidiary Reveals Encouraging Data From Early-Stage Cancer Study | Benzinga
Beyond Cancer Ltd, an affiliate of Beyond Air Inc (NASDAQ: XAIR), announced that the Phase 1 Study evaluating ultra-high concentration nitric oxide (UNO) in advanced, relapsed or refractory unresectable, primary or metastatic cutaneous and subcutaneous solid tumors has cleared the first cohort of 25,000 ppm single dose by the ...